Rectal Cancer Immunotherapy, Pediatric Weekly Insulin, and a Superbug Reckoning

The past ten days brought a pair of consequential drug approvals, a genomics finding that may reshape who gets screened for prostate cancer, and a sharply revised public-health account of how far antibiotic resistance has progressed — while new research argues the prescription pad is not the primary lever for reversing it.

FDA Clears Dostarlimab as First Immunotherapy for Certain Rectal Cancers

The U.S. Food and Drug Administration granted accelerated approval on 19 October to dostarlimab (Jemperli, GSK) for adults with stage II or III locally advanced rectal cancer whose tumours carry a particular DNA-repair defect — microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) — making it the first immunotherapy approved specifically for this cancer site.

Dostarlimab is an anti-PD-1 monoclonal antibody. Tumours with MSI-H or dMMR status accumulate large numbers of mutations because their DNA-repair machinery is broken; that unusually high mutational load is recognised by the immune system, and PD-1 blockade releases the brakes that tumour cells use to suppress that recognition. This is the same principle underlying pembrolizumab's success in MSI-H colorectal cancers elsewhere in the bowel, now applied specifically to the rectum.

The efficacy data come from the single-arm, phase 2 AZUR-1 trial. Independent central reviewers found that 47% of evaluable patients achieved a clinical complete response — no detectable tumour sign — sustained for 12 months (95% CI, 27%–56%); investigator assessments placed the figure at 68% across 98 of 144 participants. Serious adverse reactions occurred in 20% of patients, most commonly fatigue, rash, diarrhoea, and immune-related skin changes.

The clinical weight of this approval rests less in the response rates themselves and more in what a sustained complete response might mean: for patients who maintain it, oncologists can consider deferring or avoiding the surgery and chemoradiation that have defined rectal cancer care for decades and that carry lasting effects on bowel function, continence, and quality of life. Because this is an accelerated approval based on response rate rather than overall survival, confirmatory evidence is still required, and patients and clinicians should discuss the evidence maturity when weighing this option.

First Once-Weekly Basal Insulin Approved for Children with Type 2 Diabetes

Insulin icodec-abae (Awiqli, Novo Nordisk) received FDA approval on 23 October for children aged 10 and older with type 2 diabetes, marking the first once-weekly basal insulin available for paediatric patients. The adult indication for Awiqli had been granted in March 2026; this expansion follows.

Where a standard daily basal regimen requires seven injections per week, Awiqli requires one. For an adolescent managing diabetes alongside school, sport, and the ordinary social pressures of growing up, that reduction in injection frequency could meaningfully ease treatment adherence and quality of life. Type 2 diabetes in children and adolescents has increased substantially over the past two decades alongside rising obesity rates, and the condition tends to progress more rapidly in young people than in adults — making effective glycaemic control early in the disease course particularly important.

The expanded approval rests on data from the adult ONWARDS programme — six phase 3 trials demonstrating Awiqli's non-inferiority to once-daily basal insulins — combined with a single-dose pharmacokinetic study in children aged 10 to 17 confirming that the drug behaves similarly in younger patients. Safety and efficacy in children under 10 or in type 1 diabetes have not been established. Common adverse effects include hypoglycaemia, injection-site reactions, and weight gain, consistent with insulin class effects.

Oxford Study Maps Blood Proteins That Forecast Prostate Cancer Risk More Than 15 Years Out

An Oxford Population Health team analysed more than 6,000 circulating proteins in blood samples from over 2,500 men followed for approximately 16 years, looking for signatures that predated a subsequent prostate cancer diagnosis. Their results, published in European Urology, identified 12 proteins associated with prostate cancer diagnosed more than 15 years later, and seven of those were linked specifically to aggressive or fatal disease.

The most clinically striking finding was the protein ANKRD1, which appeared elevated in blood long before cancers that ultimately metastasised or proved lethal. A second protein, GZMK — produced by immune cells — may reflect early immune surveillance that temporarily holds a developing tumour in check; its presence could mark a window during which the cancer exists but is not yet progressing.

These findings are early-stage translational research, not a clinical tool. PSA testing, imperfect as it is, remains the primary screening option. An independent expert quoted in commentary cautioned that some protein associations may have arisen by chance in a dataset of this size, and that validation in independent cohorts is essential before any clinical application could be considered. If validated, however, a panel of proteins that identifies men at highest risk of aggressive prostate cancer could enable more targeted screening — concentrating the benefits of early detection on those who need it most while reducing overdiagnosis in those who do not.

Drug-Resistant Infections Now Kill More Than 50,000 Americans Annually, CDC Reports

The CDC's updated Antimicrobial Resistance Threats Report, released this week, estimates annual US deaths from drug-resistant bacteria and fungi at more than 50,000, with approximately 9.7 million infections per year — a substantial upward revision from the agency's 2019 benchmarks of roughly 35,000 deaths and 2.8 million infections. Reporting citing the CDC flags carbapenem-resistant Enterobacterales and carbapenem-resistant Acinetobacter as the most urgent threat organisms: bacteria capable of causing invasive bloodstream infections with very few remaining antibiotic options.

The size of the revision reflects improved surveillance methodology and updated modelling as much as a single dramatic rise, but the direction of travel is unambiguous. Resistance is spreading faster than new antibiotics are being approved to replace failing ones. The past decade has seen several once-promising antimicrobials fail in late-stage trials, and the commercial incentives for antibiotic development remain structurally weak relative to other pharmaceutical categories.

For European and Mediterranean health systems, the burden is not remote. Prior European Centre for Disease Prevention and Control data have consistently shown that southern European countries — including Greece, Italy, and Cyprus — carry disproportionately high rates of carbapenem-resistant organisms compared with northern Europe, a pattern linked to higher antibiotic consumption, specific farming practices, and healthcare transmission chains. The CDC update is a prompt to treat resistance as a shared regional crisis rather than a distant American problem.

Resistance Spreads Through the Environment, Not Just the Clinic

A modelling study from the London School of Hygiene & Tropical Medicine, published in One Earth, reaches a conclusion that complicates a common assumption about antimicrobial resistance control: restricting antibiotic prescribing, though important, may have less impact on the spread of resistance in the community than addressing environmental transmission routes.

Using a multi-route transmission model, the researchers found that resistant bacterial genes can persist and circulate through wastewater systems, soil, rivers, and food chains independently of how much antibiotic is prescribed in hospitals or primary care. Interventions targeting environmental reservoirs — improved wastewater treatment, reduced agricultural antibiotic use, controls on pharmaceutical manufacturing effluent — were predicted to outperform prescribing reduction alone in slowing the rate at which resistance spreads through populations.

A parallel study from the University of Connecticut, published in Frontiers in Veterinary Science this month, found that plant-based antimicrobials in poultry production may reduce horizontal gene transfer — the mechanism by which bacteria swap resistance genes between species — without relying on conventional antibiotics. Together, the two studies argue for a One Health framework in which human medicine, veterinary medicine, and environmental stewardship are treated as interconnected challenges rather than siloed policy areas. For Mediterranean countries where intensive farming, coastal water quality, and elevated antibiotic use intersect, the policy implications are direct and actionable.

The content above is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health management.